CTI BioPharma Corp. (NASDAQ:CTIC)

CAPS Rating: 1 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Recs

2
Player Avatar kanstockman (< 20) Submitted: 6/11/2007 2:45:48 PM : Underperform Start Price: $105.60 CTIC Score: +141.65

2008 a drug in Phase III stage II should be on the market with a half a billion in sales by the 2nd Q. Right now the stock is being dragged down by the sector componants.

Report this Post 2 Replies
Member Avatar tonytheoak (< 20) Submitted: 3/21/2009 7:45:20 PM
Recs: 0

what drug were you referring to?

Member Avatar floorsurgeon (< 20) Submitted: 6/14/2009 11:51:40 AM
Recs: 0

can you be more specific on what sector componants you are referring to ?

Featured Broker Partners


Advertisement